FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150871301> ?p ?o ?g. }

• W2150871301 endingPage "345" @default.
• W2150871301 startingPage "338" @default.
• W2150871301 abstract "PurposeTo compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and 125I transperineal permanent prostate seed implant (125I) for patients with low-risk prostate cancer.Methods and MaterialsBetween 1998 and 2004, a total of 374 low-risk patients (prostate-specific antigen < 10 ng/ml, T1c–T2b, Gleason score of 6 or less, and no neoadjuvant hormones) were treated at Fox Chase Cancer Center (216 IMRT and 158 125I patients). Median follow-up was 43 months for IMRT and 48 months for 125I. The IMRT prescription dose ranged from 74–78 Gy, and 125I prescription was 145 Gy. Acute and late gastrointestinal (GI) and genitourinary (GU) toxicity was recorded by using a modified Radiation Therapy Oncology Group scale. Freedom from biochemical failure was defined by using the Phoenix definition (prostate-specific antigen nadir + 2.0 ng/ml).ResultsPatients treated by using IMRT were more likely to be older and have a higher baseline American Urological Association symptom index score, history of previous transurethral resection of the prostate, and larger prostate volumes. On multivariate analysis, IMRT was an independent predictor of lower acute and late Grade 2 or higher GU toxicity and late Grade 2 or higher GI toxicity. Three-year actuarial estimates of late Grade 2 or higher toxicity were 2.4% for GI and 3.5% for GU by using IMRT compared with 7.7% for GI and 19.2% for GU for 125I, respectively. Four-year actuarial estimates of freedom from biochemical failure were 99.5% for IMRT and 93.5% for 125I (p = 0.09).ConclusionsThe IMRT and 125I produce similar outcomes, although IMRT appears to have less acute and late toxicity. To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and 125I transperineal permanent prostate seed implant (125I) for patients with low-risk prostate cancer. Between 1998 and 2004, a total of 374 low-risk patients (prostate-specific antigen < 10 ng/ml, T1c–T2b, Gleason score of 6 or less, and no neoadjuvant hormones) were treated at Fox Chase Cancer Center (216 IMRT and 158 125I patients). Median follow-up was 43 months for IMRT and 48 months for 125I. The IMRT prescription dose ranged from 74–78 Gy, and 125I prescription was 145 Gy. Acute and late gastrointestinal (GI) and genitourinary (GU) toxicity was recorded by using a modified Radiation Therapy Oncology Group scale. Freedom from biochemical failure was defined by using the Phoenix definition (prostate-specific antigen nadir + 2.0 ng/ml). Patients treated by using IMRT were more likely to be older and have a higher baseline American Urological Association symptom index score, history of previous transurethral resection of the prostate, and larger prostate volumes. On multivariate analysis, IMRT was an independent predictor of lower acute and late Grade 2 or higher GU toxicity and late Grade 2 or higher GI toxicity. Three-year actuarial estimates of late Grade 2 or higher toxicity were 2.4% for GI and 3.5% for GU by using IMRT compared with 7.7% for GI and 19.2% for GU for 125I, respectively. Four-year actuarial estimates of freedom from biochemical failure were 99.5% for IMRT and 93.5% for 125I (p = 0.09). The IMRT and 125I produce similar outcomes, although IMRT appears to have less acute and late toxicity." @default.
• W2150871301 created "2016-06-24" @default.
• W2150871301 creator A5019661851 @default.
• W2150871301 creator A5023976830 @default.
• W2150871301 creator A5030553105 @default.
• W2150871301 creator A5030829907 @default.
• W2150871301 creator A5035208282 @default.
• W2150871301 creator A5049646055 @default.
• W2150871301 creator A5062316800 @default.
• W2150871301 creator A5063389942 @default.
• W2150871301 date "2008-06-01" @default.
• W2150871301 modified "2023-10-16" @default.
• W2150871301 title "A Comparison of Acute and Chronic Toxicity for Men With Low-Risk Prostate Cancer Treated With Intensity-Modulated Radiation Therapy or 125I Permanent Implant" @default.
• W2150871301 cites W1969027862 @default.
• W2150871301 cites W1969355197 @default.
• W2150871301 cites W1978906140 @default.
• W2150871301 cites W1981976495 @default.
• W2150871301 cites W1989920747 @default.
• W2150871301 cites W1994339219 @default.
• W2150871301 cites W1997716779 @default.
• W2150871301 cites W2016557692 @default.
• W2150871301 cites W2023807811 @default.
• W2150871301 cites W2045578658 @default.
• W2150871301 cites W2056643793 @default.
• W2150871301 cites W2062416248 @default.
• W2150871301 cites W2064057265 @default.
• W2150871301 cites W2064382689 @default.
• W2150871301 cites W2070052669 @default.
• W2150871301 cites W2071365490 @default.
• W2150871301 cites W2079491491 @default.
• W2150871301 cites W2093867637 @default.
• W2150871301 cites W2103290459 @default.
• W2150871301 cites W2104874527 @default.
• W2150871301 cites W2117688819 @default.
• W2150871301 cites W2117792530 @default.
• W2150871301 cites W2118971672 @default.
• W2150871301 cites W2121495561 @default.
• W2150871301 cites W2153674426 @default.
• W2150871301 cites W2157797729 @default.
• W2150871301 cites W2169594765 @default.
• W2150871301 cites W2172038823 @default.
• W2150871301 cites W4237084318 @default.
• W2150871301 cites W4293241248 @default.
• W2150871301 doi "https://doi.org/10.1016/j.ijrobp.2007.10.019" @default.
• W2150871301 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2763097" @default.
• W2150871301 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18207665" @default.
• W2150871301 hasPublicationYear "2008" @default.
• W2150871301 type Work @default.
• W2150871301 sameAs 2150871301 @default.
• W2150871301 citedByCount "75" @default.
• W2150871301 countsByYear W21508713012012 @default.
• W2150871301 countsByYear W21508713012013 @default.
• W2150871301 countsByYear W21508713012014 @default.
• W2150871301 countsByYear W21508713012015 @default.
• W2150871301 countsByYear W21508713012016 @default.
• W2150871301 countsByYear W21508713012017 @default.
• W2150871301 countsByYear W21508713012018 @default.
• W2150871301 countsByYear W21508713012019 @default.
• W2150871301 countsByYear W21508713012020 @default.
• W2150871301 countsByYear W21508713012021 @default.
• W2150871301 countsByYear W21508713012023 @default.
• W2150871301 crossrefType "journal-article" @default.
• W2150871301 hasAuthorship W2150871301A5019661851 @default.
• W2150871301 hasAuthorship W2150871301A5023976830 @default.
• W2150871301 hasAuthorship W2150871301A5030553105 @default.
• W2150871301 hasAuthorship W2150871301A5030829907 @default.
• W2150871301 hasAuthorship W2150871301A5035208282 @default.
• W2150871301 hasAuthorship W2150871301A5049646055 @default.
• W2150871301 hasAuthorship W2150871301A5062316800 @default.
• W2150871301 hasAuthorship W2150871301A5063389942 @default.
• W2150871301 hasBestOaLocation W21508713012 @default.
• W2150871301 hasConcept C116263406 @default.
• W2150871301 hasConcept C121608353 @default.
• W2150871301 hasConcept C126322002 @default.
• W2150871301 hasConcept C126894567 @default.
• W2150871301 hasConcept C133507102 @default.
• W2150871301 hasConcept C141071460 @default.
• W2150871301 hasConcept C2776235491 @default.
• W2150871301 hasConcept C2778311097 @default.
• W2150871301 hasConcept C2780192828 @default.
• W2150871301 hasConcept C2781406297 @default.
• W2150871301 hasConcept C29730261 @default.
• W2150871301 hasConcept C509974204 @default.
• W2150871301 hasConcept C71924100 @default.
• W2150871301 hasConceptScore W2150871301C116263406 @default.
• W2150871301 hasConceptScore W2150871301C121608353 @default.
• W2150871301 hasConceptScore W2150871301C126322002 @default.
• W2150871301 hasConceptScore W2150871301C126894567 @default.
• W2150871301 hasConceptScore W2150871301C133507102 @default.
• W2150871301 hasConceptScore W2150871301C141071460 @default.
• W2150871301 hasConceptScore W2150871301C2776235491 @default.
• W2150871301 hasConceptScore W2150871301C2778311097 @default.
• W2150871301 hasConceptScore W2150871301C2780192828 @default.
• W2150871301 hasConceptScore W2150871301C2781406297 @default.
• W2150871301 hasConceptScore W2150871301C29730261 @default.
• W2150871301 hasConceptScore W2150871301C509974204 @default.
• W2150871301 hasConceptScore W2150871301C71924100 @default.
• W2150871301 hasIssue "2" @default.

• next